STOCK TITAN

Hoth Therapeutics Inc - HOTH STOCK NEWS

Welcome to our dedicated news page for Hoth Therapeutics (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hoth Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hoth Therapeutics's position in the market.

Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) to Present at NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
conferences acquisition
-
Rhea-AI Summary
Hoth Therapeutics announces new subsidiary to screen for rare disease therapeutics using AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
AI
-
Rhea-AI Summary
Hoth Therapeutics receives Pre-IND meeting approval from FDA for HT-KIT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
Rhea-AI Summary
Hoth Therapeutics closes registered direct offering, raising approximately $2.89 million in gross proceeds. Proceeds to be used for general working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
-
Rhea-AI Summary
Hoth Therapeutics announces purchase and sale of 1.1M shares of common stock at $2.63 per share in a registered direct offering. Gross proceeds expected to be approximately $2.89M. Proceeds to be used for general working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.36%
Tags
-
Rhea-AI Summary
Hoth Therapeutics announces positive preclinical results for HT-KIT in the treatment of advance systemic mastocytosis and gastrointestinal stromal tumors (GISTs)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.36%
Tags
none
Rhea-AI Summary
Hoth Therapeutics submits request for Pre-IND meeting with FDA for HT-KIT cancer therapeutic
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.16%
Tags
-
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced positive results from its Phase 1b clinical trial of BioLexa for atopic dermatitis. The trial showed a 35% improvement in SCORAD measurement and a 60% improvement in EASI measurement, with a 46% improvement in patient quality of life according to DLQI. BioLexa outperformed gentamicin lotion and placebo in all aspects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
-
Rhea-AI Summary
Hoth Therapeutics' HT-ALZ shows positive preclinical results for Alzheimer's Disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) Announces Dosing of First Patient in Phase 2a Clinical Trial for HT-001, a Treatment for Skin Toxicities Related to EGFR Inhibitors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
Hoth Therapeutics Inc

Nasdaq:HOTH

HOTH Rankings

HOTH Stock Data

5.96M
4.10M
1.62%
6.98%
4.95%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
New York

About HOTH

hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio